Rothschild & Co Redburn Has Lowered Expectations for Medtronic (NYSE:MDT) Stock Price

Medtronic (NYSE:MDT) had its price target decreased by equities researchers at Rothschild & Co Redburn from $111.00 to $106.00 in a note issued to investors on Friday,MarketScreener reports. The firm currently has a “buy” rating on the medical technology company’s stock. Rothschild & Co Redburn’s price objective suggests a potential upside of 28.33% from the stock’s current price.

A number of other equities analysts have also recently commented on the company. Needham & Company LLC lowered their target price on Medtronic from $120.00 to $101.00 and set a “buy” rating for the company in a report on Wednesday. Wells Fargo & Company reduced their price target on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday. Evercore set a $106.00 price objective on shares of Medtronic and gave the company an “outperform” rating in a research note on Thursday, April 9th. Piper Sandler dropped their price objective on shares of Medtronic from $91.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Mizuho cut their target price on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Wednesday. Seventeen equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.00.

Medtronic Trading Up 0.8%

NYSE:MDT traded up $0.67 during trading hours on Friday, reaching $82.60. 1,870,938 shares of the stock were exchanged, compared to its average volume of 9,168,656. Medtronic has a twelve month low of $73.31 and a twelve month high of $106.33. The business has a 50-day moving average of $81.58 and a two-hundred day moving average of $92.11. The company has a market capitalization of $106.05 billion, a price-to-earnings ratio of 22.13, a PEG ratio of 1.89 and a beta of 0.58. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. The business had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.20%.The company’s revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities analysts predict that Medtronic will post 5.97 EPS for the current year.

Institutional Investors Weigh In On Medtronic

Several institutional investors have recently added to or reduced their stakes in MDT. Vanguard Group Inc. lifted its position in shares of Medtronic by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock worth $12,388,027,000 after buying an additional 1,888,381 shares during the last quarter. State Street Corp grew its position in shares of Medtronic by 2.0% in the 4th quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock valued at $5,966,780,000 after buying an additional 1,199,621 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Medtronic by 2.7% during the 4th quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock worth $5,150,420,000 after acquiring an additional 1,419,730 shares in the last quarter. Capital Research Global Investors lifted its position in Medtronic by 12.6% in the fourth quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after acquiring an additional 3,880,174 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Medtronic by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 27,879,481 shares of the medical technology company’s stock valued at $2,665,832,000 after acquiring an additional 231,919 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported fiscal Q4 revenue of $9.81 billion, topping estimates, while adjusted EPS of $1.55 matched expectations; management also highlighted strong performance in Cardiac Ablation Solutions and cardiovascular products. Medtronic (MDT) Climbs 5.7% on Stellar Q4
• Positive Sentiment: The company raised its quarterly dividend to $0.72 per share and issued FY2027 guidance for 6.75%–7.25% organic revenue growth, reinforcing confidence in the long-term outlook. Medtronic Stock Is Defying a Market Selloff After Earnings. Here’s Why.
• Positive Sentiment: Analyst commentary has been constructive, with BTIG upgrading Medtronic to Buy and TD Cowen and RBC reiterating bullish ratings, citing accelerating organic growth and a strong innovation pipeline. Wall Street May Be Mispricing Medtronic, Analyst Says
• Neutral Sentiment: Medtronic is expanding its Hugo robotic surgery platform in the U.S., which could support future growth, but the near-term impact is still developing. Medtronic Balances Hugo Robotics Expansion With Ongoing Cardiovascular Device Recalls
• Negative Sentiment: Some firms trimmed price targets and kept neutral/hold ratings, and the company is still dealing with cardiovascular device recalls and margin concerns that could weigh on sentiment. Medtronic Balances Hugo Robotics Expansion With Ongoing Cardiovascular Device Recalls

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).